Monday was one of those days where the market indices told one story while individual stocks told quite another. The Dow Jones slipped around 200 points, but a surprising mix of companies across biotech, defense tech, and commodities posted some seriously impressive gains.
Defense Contract Sends Planet Labs Higher
Leading the charge was Planet Labs PBC (PL), which jumped 7% to $24.29 after announcing a multi-year, nine-figure agreement with the Swedish Armed Forces. It's the kind of defense contract that validates the company's satellite imaging technology and signals growing international demand for commercial space capabilities in military applications.
Biotech Companies Shine on Revenue Reports
The real action, though, was in biotechnology, where several companies posted explosive gains after releasing preliminary financial results that exceeded expectations.
Day One Biopharmaceuticals Inc (DAWN) led the biotech rally with a 24.7% surge to $11.15. The company reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year over year. That's the kind of revenue acceleration that gets investors excited about a commercial-stage drug.
RxSight Inc (RXST) wasn't far behind, gaining 22.7% to $10.85 after announcing preliminary fourth-quarter revenue of $32.6 million. Meanwhile, Beam Therapeutics Inc (BEAM) rose 22% to $33.60 on news of its 2026 strategic priorities, alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302, and preliminary estimated cash of $1.25 billion at the end of 2025.
Adaptive Biotechnologies Corp (ADPT) climbed 13.4% to $17.86 after reporting preliminary fourth-quarter revenue of $72 million and 2025 revenue of $277 million. Twist Bioscience Corp (TWST) gained 11.7% to $39.48 on preliminary fiscal first-quarter 2026 revenue of $103.7 million, up 17% year-over-year and ahead of guidance.
Zenas Biopharma Inc (ZBIO) surged 23.2% to $19.81, while Abivax SA (ABVX) gained 8.3% to $123.88.




